GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinocelltech Group Ltd (SHSE:688520) » Definitions » 3-Year Revenue Growth Rate

Sinocelltech Group (SHSE:688520) 3-Year Revenue Growth Rate : 159.30% (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Sinocelltech Group 3-Year Revenue Growth Rate?

Sinocelltech Group's Revenue per Share for the three months ended in Mar. 2025 was ¥1.06.

During the past 12 months, Sinocelltech Group's average Revenue per Share Growth Rate was 3.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was 159.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was 460.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 9 years, the highest 3-Year average Revenue per Share Growth Rate of Sinocelltech Group was 1518.80% per year. The lowest was -60.30% per year. And the median was 238.00% per year.

Competitive Comparison of Sinocelltech Group's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Sinocelltech Group's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sinocelltech Group's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sinocelltech Group's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Sinocelltech Group's 3-Year Revenue Growth Rate falls into.


;
;

Sinocelltech Group 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Sinocelltech Group  (SHSE:688520) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Sinocelltech Group 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Sinocelltech Group's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinocelltech Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinocelltech Group Ltd (SHSE:688520) » Definitions » 3-Year Revenue Growth Rate
Comparable Companies
SZSE:301301 SHSE:688266 SZSE:002007 SHSE:688278 SHSE:688166 SZSE:002821 SHSE:688336 SHSE:688382 SHSE:603233 SZSE:300204 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:UCB XBRU:ARGX ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
Kechuang Seventh Street, Beijing Economic and Technological Development Zone, Room 307, Building 5, Courtyard 31, Beijing, CHN, 100176
Website
http://www.sinocelltech.com
Sinocelltech Group Ltd is engaged in development and industrialization of biopharmaceutical products such as monoclonal antibodies, recombinant proteins and vaccines. The company has developed technology platforms in protein expression vectors, cell line development, serum-free medium development, stoichiometrically controlled fed-batch cell culture, process scale-up, and protein purification. Its capacities include stable CHO cell line development, cell banking and certification, serum-free and protein-free culture medium development, fed-batch cell culture process development, optimization, and process scale-up; protein purification development, and large scale production.
Executives
Xie Liang Zhi Director

Sinocelltech Group Headlines

No Headlines